Tongxieyi Forum # 93
2019 SAPA Healthcare Investment
Forum & Roadshow
Sino-American Pharmaceutical Professionals Association (SAPA)
In Collaboration with Tongxieyi New Drug Elite Club
June 14– 17, 2019
New York, New Jersey, Maryland USA
Shenzhen Share Capital Co., Ltd.
SAPA in collaboration with Tongxieyi will hold a Sino-US Healthcare Investment Forum and Road Show on June 14-15, 2019 in New Jersey and New York, USA.
SAPA was founded in 1993 in the US as a non-profit organization and since then has grown rapidly and become one of the most active and well-recognized professional organizations in the US with a membership base of over 6,000. SAPA is headquartered in the Greater New York area (NJ/NY/CT) with six US regional chapters (SAPA-NE in New England, SAPA-GP in Greater Philadelphia, SAPA-CT in Connecticut, SAPA-DC in Greater Washington DC area, SAPA-MW in Midwest area, and SAPA-West in West Coast), and one chapter in China. SAPA members are engaged in drug discovery, pre-clinical & clinical development, manufacturing, regulation, marketing, and distribution of pharmaceuticals and biotech therapeutic products. To fulfill its missions, each year SAPA and its regional chapters organize and sponsor many events including annual conference, scientific symposia, seminars, workshops, and social activities both in the US and China. These events have been supported and sponsored by many organizations, including major pharmaceutical, biotech and CRO companies as well as many Bio-Parks and Development Zones in China.
With 15 years history of devotion and hard-working in the field of biomedical R&D and innovation in China, Tongxieyi has held more than 90 sessions of forums. "Tongxieyi" is an important value sharing platform of pharmaceutical elites both in academic and industrial, and an important source of the new ideas of Chinese new drug R&D.
SAPA Investment Forum is an important event. This year’s event will feature investment hot topics in both the US and China. Tongxieyi will organize the sessions on Day 1, and will actively participate the sessions on Day 2. Investors and invited speakers will introduce the new trends and future of pharmaceutical industry, and share their experiences in entrepreneurship, finance and development. The event further promote business cooperation between US and China.
We will also collaborate with the SAPA-DC Chapter to plan events in DC areas, to learn more about policy and regulation from the experts of the US FDA. Working together with SAPA, Tongxieyi will create a great opportunity of learning and collaboration in healthcare advancement and development.
June 14 , 2019（Friday）
China Healthcare Investment and Innovation Forum
hosted by Tongxieyi Forum
8:00 am-9:00 am Registration
9:00 am-11:45 am Morning Session： Incentivising Innovation in Biomedical and Pharma Industry
9:00am -9:15 am
l Welcome Remarks & Opening Address (SAPA & Tongxieyi Representatives)
l Keynote Speeches (SAPA & Tongxieyi Representatives)
9:15am-9:45 am New Challenges and Opportunities in Chinese Pharmaceutical Industry
Dr. Tom Du Partner, Share Capital, Humphries Pharmaceutical Consulting, LLC（HPC）
Dr. Tom Du is currently working as a partner of Share Capital, and also as the Chief Consultant of Humphries Pharmaceutical Consulting. Dr. Du is a physician and also a scientist. He graduated from Tianjin Medical University (TMU). He got his training in medicine at TMU and in pathology at McGill University, Montreal. Before joining the US Food and Drug Administration (FDA) as a reviewing officer in 1994, he had two years of fellowship training at Harvard University. When he worked at the FDA, Dr. Du worked in the Division of Pulmonary, Allergy and Rheumatology Products, and then worked in the Division of Oncology Products. He reviewed more than one hundred INDs and NDAs. Since leaving the FDA in 2000, he has held several important positions in the pharmaceutical industry. He worked as Senior Director, Clinical and Regulatory Affairs, Hutchison Whampoa Company based in Hong Kong. He served as Acting Managing Director, China operations, and then worked as Senior Director, Global Regulatory Affairs at Ingenix Pharmaceutical Services, a UnitedHealth Group Company.
09:45am-10:15am Shared Ambition, Real Solution——Entrepreneurial Stories of HAICHANG BioTech
l 3 ways to (not) kill your dreams
l 3 actions to make a dream coming true for startup
l From 0 to1: understanding the phases of a startup
l From 1 to 10: What it takes to translate a $1M startup into a $100M scale-up?
Dr. Ben ZHAO CEO, Zhejiang HAICHANG Bio-Tech Co., Ltd.
Ben Zhao is founder and CEO of The WhiteOak Group Inc. (TWG). Prior to TWG, Dr. Zhao is a CMC reviewer and GMP inspector specialized in complex drugs at the US FDA. In 2014, he founded TWG devoted to develop high-quality liposomal drugs with rational design. Previously, Dr. Zhao was a group leader in developing small interfering RNA (siRNA) at Abbott Laboratories. In China, he developed the first generic liposomal doxorubicin (Libaoduo®) in 2008. Dr. Zhao is an inventor of 12 patents and has published over twenty peer reviewed articles. He also serves as an Advisory Board member for the NSF Nanotechnology center. Dr. Zhao was trained as a medical doctor at Norman Bethune University of Medical Sciences and received a Ph.D. degree from the Ohio State University.
10:15am-10:45am Precision Medicine: Reshaping the Future of Healthcare Industry
Mr. Frank HUANG Partner, Share Capital
Frank has 20+ years of experience in management and investment in the healthcare industry. Before joining Share Capital, Frank was Head of Finance Department of Philips Consumer Communications, L.P., CFO of Walmart Inc. China, and executive board member of a few public listed companies. He has invested over 70 portfolio companies and executed a number of successful IPOs and exits. Frank received his B.A. in Accounting from Jiangsu University and attained his MBA from CEIBS.
10:45 am-11:15 am Progress of Chinese Healthcare Reform and Investment Climate for Venture Capitalists
Ms. Kathy XIE Managing Director, Share Capital
Managing Director, Healthcare Fund of Share Capital, Bachelor of Finance from Guanghua School of Management of Peking University, and MBA from China Europe International Business School. Three years of financial auditing experience of high-tech multinational enterprises at KMPG, and 8 years venture capital investment experience at Share Capital, mainly covering the fields of health services, digital health, medicine circulation and commercial health insurance.
11:15 am-11:45 am Panel Discussion hosted by Kathy XIE
Incentivising Innovation in Biomedical and Pharma Industry in China Speakers from the morning sessions
11:45 am-1:30 pm Lunch
1:30 pm-4:20 pm Afternoon Session
Pharmaceutical Innovation and Entrepreneurship from Returned Overseas Elites
1:30 pm-2:00 pm Opportunities for Overseas Chinese Talents
Mr. Richard ZHOU Managing Director, Share Capital
2:00pm-2:30pm An Entrepreneur's Perspective: How to Survive in the Uncertainties
Dr. Bo LIANG Former SAPA-GP President, CEO, IVIEW Therapeutics, Inc.
Dr. Bo Liang is an entrepreneur with over 20 years experience in drug discovery and research, including chemical and material sciences, biotechnology and materials venture and management. Dr. Liang is Founder and President of IVIEW Therapeutics Inc., focusing on developing ophthalmic and wound care medications. The lead compound, IVIEW-1201 for ophthalmic indications, is scheduled to start phase II clinical trials in 2019. He is also co-founder and Chairman of Adesso Advanced Materials, which developed revolutionary re-workable and recyclable epoxy resin systems and were qualified in carbon fiber composites in automotive industry applications, especially for light weight new energy vehicles. He is also Managing Partner of Alpha Bioventure, an Angel Investment Fund dedicating to life sciences innovative projects.
2:30pm-3:00pm Innovative T-cell Engaging Bispecifics to Fight Cancer
Dr. Sam LIU CEO, Shenzhen Enduring Biotech, Ltd.
Shumin Liu, PhD., CEO and founder of Shenzhen Enduring Biotech Ltd (SZEB).
Dr Liu has over 10 years of pharmaceutical industrial experiences, expert on biologics development, including early research and development, GMP manufacturing and regulatory filing. Before he founded and served CEO at SZEB, Dr. Liu was a manager of clinical manufacturing in Bristol-Myers Squibb, responsible for tech transfers from development stage to manufacturing, quality related investigations and IND filing. Before that, Dr Liu held a senior scientist position at Enzon pharmaceuticals and served a leading role in two marketed product developments, Adagen® and Oncaspar®. while leading many other pharmaceutical product developments including pegylations of single antibody fragments, interferons, C1 esterase inhibitors, etc.
3:00pm-3:30pm Novel Anti-Cancer Drugs Make Chemotherapy Safer and More Effective
l Cancer cells and immune cells both depend on specific metabolic pathways to elicit responses.
l Targeting immunometabolism is an attractive strategy to make chemotherapy safer and more effective.
Dr. Peter MU CEO, Teamed On International, LLC.
Dr. Mu is founder and CEO of TeamedOn International, Inc., an early-stage immuno-metabolism therapeutic company headquartered in Gaithersburg, Maryland. Under his leadership, TeamedOn has advanced novel therapeutic programs for cancer and diabetic nephropathy, and successfully raised federal, state, and private financings. Prior to his current role, Dr. Mu was an independent consultant for 7 years, he led and contributed to multiple pharmaceutical development projects, ranged from IND to successful NDA. Dr. Mu also held management positions at WuXi AppTec, Lexicon Pharmaceuticals, and Covance Laboratories. Dr. Mu received a PhD in Toxicology at North Carolina State University and an MBA at the Johns Hopkins University.
3:30pm-4:00pm Panel Discussion
Pharmaceutical Innovation and Entrepreneurship from Returned Overseas Elites Speakers from the afternoon sessions
4:30 pm-7:00 pm Cocktail Reception and Networking
7:00 pm-9:00 pm Share Capital’s Salon (by Invitation)
June 15 , 2019 （Saturday）
2019 SAPA Healthcare Investment Forum & Roadshow
hosted by SAPA
8:00 am – 9:00 am Registration
9:00 am - 9:20 am Icebreaker & Networking
Introduction & Opening Remarks
9:20 am - 9:35 am Special Invitation Speech
9:35 am - 10:55 am Keynote Speech & Plenary Session
l Investment Treads on Pharma and Life Science
l Current Hot Topics
l Entrepreneur Journey
10:55 am - 11:10 am Coffee Break
11:10 am -11:50 am Fireside Chat Session I: Investment
11:50 am -12:30 pm Fireside Chat Session II: Entrepreneurship
12:30 pm - 1:30 pm Networking Luncheon
1:30 pm - 5:30 pm Parallel Sessions
l Pre-Scheduled Private 1:1 Sessions
l Roadshow Oral Presentation
l Entrepreneur Clinics
l Tech Transfer Office
June 17, 2019 （Monday）
2:00 pm - 4:00 pm Theme: Technological and regulatory factors in new drug investment
Networking Salon (by Invitation)
Promotion and display
This forum can provide enterprises and institutions with name salons, exhibition booths, advertisements, and other publicity and display.
Online registration is open. Limited seats available. Please register as soon as possible between April 10 to June 13 at http://Tongxieyi92.bagevent.com
April 10 – April 30 RMB 5,000 yuan per person
May 1 - May 15 RMB 5,500 yuan per person
May 16 - June 13 RMB 6,000 yuan per person
Freehand Annual Membership:
April 10 - May 15 RMB 4,000 yuan per person
May 16 - June 13 RMB 5,000 yuan per person
On-site registration: RMB 6,000 yuan per person
Registration fees include lunch, dinner and coffee break on June 14, 15 and 17. Forum information will be shared with participants after the meeting.To become a freehand member, you can enjoy multiple privileges. Application for membership can be consulted with the Freehand Secretariat by WeChat: txymsc.
Accommodation and Transportation
· DoubleTree by Hilton Somerset Hotel and Conference Center, 200 Atrium Drive, Somerset, NJ 08873
· Columbia University, New York
Air ticket, Hotel booking and pick-up service are available upon request.
Ma Jun 158-1018-0670
Zhang Mingyue 151-0168-6528
Guang Meng 177-1025-9225
Exhibitor contact: Li Jiayuan 17718589627 Cheng Zengjiang 13511067090
We welcome on-site exhibitions and other business cooperation opportunities
If you are unable to attend the meeting due to special circumstances, please submit cancellation instructions (e-mail to txy@Tongxieyi.com) before May 30 (including May 30), and you will receive the full refund; cancellation after May 30, will be refunded 80%; after the beginning of the meeting, cancel the order and refund again.